Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

B-cell lymphoma cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BCL6 (3) MALT1 (2) 5-HT Receptor (1) ADC Antibody (1) Adenosine Receptor (1) Akt (1) Antibody-Drug Conjugates (ADCs) (3) Apoptosis (17) Autophagy (1) Bacterial (1) Bcl-2 Family (18) Btk (6) c-Myc (1) Caspase (2) CD19 (2) CD20 (4) CD28 (1) CD3 (2) CDK (5) DNA Alkylator/Crosslinker (1) E1/E2/E3 Enzyme (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) Endogenous Metabolite (1) HDAC (3) Histone Methyltransferase (6) HSP (1) HSV (1) IAP (1) IRAK (5) Isotope-Labeled Compounds (2) JAK (1) Ligands for E3 Ligase (6) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (2) MicroRNA (2) Microtubule/Tubulin (3) MMP (1) Molecular Glues (7) N-myristoyltransferase (1) Necroptosis (1) NEKs (1) NF-κB (1) Nucleoside Antimetabolite/Analog (1) Phosphatase (1) PI3K (2) PROTACs (1) Ras (1) Ser/Thr Protease (1) SHMT (1) STAT (2) Survivin (1) TNF Receptor (1) Transmembrane Glycoprotein (1) VEGFR (1) β-catenin (3)
By Research Areas:	Cancer (85) Endocrinology (1) Infection (1) Inflammation/Immunology (15) Neurological Disease (1)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Anaplastic lymphoma kinase (ALK) BCL6 Nuclear Factor of activated T Cells (NFAT) TREM receptor Itk TOPK MALT1 NAMPT ALCAM/CD166 GDNF Receptor VISTA Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99024

Glofitamab RO7082859	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .

HY-N3062

Pinobanksin 3,5,7-Trihydroxyflavanone	Apoptosis	Others
Pinobanksin has apoptotic induction in a B-cell lymphoma cell line .

HY-134982

Thalidomide-piperazine-Boc	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-piperazine-Boc is an intermediate that can be used in the synthesis of B-cell lymphoma 6 protein (BCL6) PROTAC .

HY-143653

BCL6-IN-6	BCL6	Cancer
BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-148281

TMX-2164	Bcl-2 Family	Cancer
TMX-2164 is a potent, irreversible B-cell lymphoma 6 (BCL6) inhibitor with an IC₅₀ value of 152 nM. TMX-2164 displays sustained target engagement and antiproliferative activity in cells .

HY-147741

DPPY	JAK Btk EGFR	Inflammation/Immunology Cancer
DPPY (compound 6) is a potent PTK inhibitor with IC₅₀ values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. DPPY shows anti-proliferative activity against B-cell lymphoma cells. DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-159817

Asaretoclax	Bcl-2 Family	Cancer
Asaretoclax is a potent B-cell lymphoma 2 (Bcl-2) inhibitor. Asaretoclax has the potential for the research of cancer .

HY-122829

BCL6 PROTAC 1	PROTACs BCL6	Cancer
BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) PROTAC. BCL6 PROTAC 1 inhibits BCL6 cell reporter with an IC₅₀ value of 8.8 µM. BCL6 PROTAC 1 significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6 PROTAC 1 can be used in tumor related research .

HY-111537

rel-AZ5576	c-Myc CDK Bcl-2 Family	Others
rel-AZ5576 is a selective CDK9 inhibitor with the activity of downregulating Mcl-1 and MYC mRNA transcription and protein expression in diffuse large B-cell lymphoma by inhibiting CDK9, promoting MYC protein turnover, reducing MYC phosphorylation on the stable Ser62 residue and downregulating MYC transcriptional targets, inhibiting the growth of diffuse large B-cell lymphoma cell lines in vitro and in vivo and independent of the cell origin.

HY-168983

Lonitoclax	Bcl-2 Family	Cancer
Lonitoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lonitoclax has comparable anti-tumor efficacy to Venetoclax (HY-15531) in both B cell and myeloid malignancy models. Lonitoclax is promising for research of relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas .

HY-P99501

Zuberitamab HS006	CD20	Cancer
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

HY-160698

SGR-1505	MALT1	Inflammation/Immunology Cancer
SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas .

HY-124295

Imofinostat MPT0E028	HDAC Akt Apoptosis	Cancer
MPT0E028 is an orally active and selective HDAC inhibitor with IC₅₀s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively . MPT0E028 reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. MPT0E028 has good anticancer activity .

HY-136268

AQX-435	Phosphatase Apoptosis	Inflammation/Immunology
AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth .

HY-N3001

Isolinderalactone	STAT VEGFR Bcl-2 Family Survivin IAP	Cancer
Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of VEGFR2 activation in endothelial cells . Isolinderalactone suppresses the expression of B-cell lymphoma 2 (Bcl-2), survi

HY-129188

CCT369260	Bcl-2 Family Molecular Glues	Cancer
CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC₅₀ of 520 nM .

HY-136640

BCL6-IN-4	Bcl-2 Family	Cancer
BCL6-IN-4 is a potent B-cell lymphoma 6 (BCL6) inhibitor with an IC₅₀ of 97 nM. BCL6-IN-4 has anti-tumor activities .

HY-131246

DM-01	Histone Methyltransferase	Cancer
DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .

HY-109029

Dezapelisib INCB040093	PI3K	Cancer
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .

HY-P99711

Loncastuximab RB4v1.2	CD19	Cancer
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .

HY-147091

Tazemetostat de(methyl morpholine)-COOH	Ligands for Target Protein for PROTAC	Cancer
Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein EZH2, which can be used to synthesis of EZH2 degraders (PROTACs). EZH2 degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma .

HY-169218

WK692	BCL6	Cancer
WK692 is a BCL6 inhibitor that inhibits the BCL6 ^BTB/SMRT interaction. WK692 can effectively inhibit the growth of diffuse large B-cell lymphoma cells and synergize with EZH2 and PRMT5 inhibitors. .

HY-P99055

Urelumab	TNF Receptor	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-161080

4'-Ethynyl-2'-deoxycytidine	Nucleoside Antimetabolite/Analog	Cancer
4'-Ethynyl-2'-deoxycytidine is an anticancer nucleoside. 4'-Ethynyl-2'-deoxycytidine can used in study acute lymphoblastic leukemia and diffuse large B-cell lymphoma .

HY-146183

BCL6-IN-9	Bcl-2 Family	Cancer
BCL6-IN-9 (compound 1) is a potent B-cell lymphoma 6 protein (BCL6) inhibitor, with an IC₅₀ of 3.9 nM. BCL6-IN-9 can be used for the research of cancer .

HY-150594

IRAK4-IN-17	IRAK NF-κB	Cancer
IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC₅₀ of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-120231

Z-VRPR-FMK	MALT1	Cancer
Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .

HY-119402

TP-021 BCL6-IN-8c	Bcl-2 Family	Cancer
TP-021 (BCL6-IN-8c) is a potent and orally active B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor with an IC₅₀ of 0.10 µM in cell-free enzyme-linked immunosorbent assay .

HY-10984A

(S)-Pomalidomide (S)-CC-4047	Endogenous Metabolite	Cancer
(S)-Pomalidomide ((S)-CC-4047) is an angiogenesis-inhibiting drug with growth-inhibitory activity against B-cell tumors. (S)-Pomalidomide can induce complete tumor regression in BurK_itt lymphoma cells. (S)-Pomalidomide serves as an immunomodulator with potential applications in inhibiting hematological malignancies .

HY-132601A

Cobomarsen sodium MRG-106 sodium	MicroRNA	Cancer
Cobomarsen sodium is an oligonucleotide inhibitor of miR-155. Cobomarsen sodium inhibits multiple gene pathways associated with cell survival (including JAK/STAT, MAPK/ERK and PI3K/AKT). Cobomarsen sodium can be used for the research of B-cell lymphoma .

HY-129226

SHMT-IN-2	SHMT	Endocrinology Cancer
SHMT-IN-2 is a stereo specific inhibitor of human SHMT1/2 with IC₅₀ values of 13 nM and 66 nM for SHMT1 and SHMT2, respectively. SHMT-IN-2 can block the growth of many human cancer cells, and has sensitivity for B-cell lymphomas .

HY-130369

NSC10010 hydrochloride	Bacterial Necroptosis HSV	Infection Cancer
NSC10010 hydrochloride inhibits gammaherpesvirus associated B-lymphomas growth through activation of NF-kB and c-Myc-mediated signaling pathways. NSC10010 hydrochloride induces necrotic cell death in gammaherpesvirus infected B-cells. NSC10010 hydrochloride is also an inhibitor of Mtb ClpC1 ATPase .

HY-161765

iHSP110-33	HSP STAT	Cancer
iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-132601

Cobomarsen MRG-106	MicroRNA	Cancer
Cobomarsen (MRG-106) is an oligonucleotide inhibitor of miR-155. Cobomarsen inhibits multiple gene pathways associated with cell survival (including JAK/STAT, MAPK/ERK and PI3K/AKT). Cobomarsen can be used for the research of B-cell lymphoma .

HY-44432

Navitoclax-piperazine ABT-263-piperazine	Bcl-2 Family Ligands for Target Protein for PROTAC	Cancer
Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604) with anti-tumor activity .

HY-12422

Voruciclib	CDK	Cancer
Voruciclib is an orally active and selective CDK inhibitor with K_i values of 0.626 nM-9.1 nM. Voruciclib potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .

HY-12422A

Voruciclib hydrochloride	CDK	Cancer
Voruciclib hydrochloride is an orally active and selective CDK inhibitor with K_i values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .

HY-103019A

(±)-Enitociclib (±)-BAY-1251152; (±)-VIP152	CDK	Cancer
(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. BAY-1251152 can be used in the study of acute myelogenous leukemia and double-hit diffuse large B-cell lymphoma .

HY-144858

EZM0414 5+ Cited Publications	Histone Methyltransferase	Cancer
EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC₅₀=18 nM in SETD2 biochemical assay; IC₅₀=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .

HY-160245

QL47R	Btk	Others
QL47R is an approximately isosteric analogue of QL47 (HY-80003). QL47R dose not inhibit the biochemical kinase activity of BTK at concentrations below 10 μM. QL47R dose not display antiproliferative activity on B-Cell Lymphoma Cell Lines at concentrations of less than 10 μM .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-155574

IRAK4-IN-27	IRAK Apoptosis	Cancer
IRAK4-IN-27 (Compound 22) is a potent, selective inhibitor of IRAK4, with IC₅₀ of 8.7 nM. IRAK4-IN-27 inhibits cell growth, and promotes apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line. IRAK4-IN-27 can be used for DLBCL study .

HY-155477

Cbl-b-IN-15	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-15 (compound 25) is an inhibitor of the RING finger E3 ligase Cbl (IC₅₀: 15 nM). Cbl-b refers to Casitas B-lineage lymphoma proto-oncogene-b, which inhibits T-cell, natural killer (NK) cell, and B-cell activation. Cbl-b-IN-15 activates T cell function with EC₅₀=0.41 μM .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-132253A

Polatuzumab vedotin (solution)	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-10293

Aderbasib INCB007839; INCB7839	MMP	Cancer
Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 ⁺ breast cancer, gliomas, et al .

HY-12649

Y16 5 Publications Verification	Ras	Cancer
Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a K_d value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP .

Cat. No.	Product Name	Target	Research Area

HY-P5472

Tumour-associated MUC1 epitope	Transmembrane Glycoprotein	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

HY-100866B

F1324 acetate	Bcl-2 Family	Cancer
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 acetate exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-100866

F1324	Bcl-2 Family	Cancer
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC₅₀ of 1 nM. F1324 exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

HY-100866A

F1324 TFA	Bcl-2 Family	Cancer
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC₅₀ of 1 nM. F1324 TFA exhibits binding t_1/2 value of 441 s and has strong inhibition activity against BCL6 PPI .

Cat. No.	Product Name	Target	Research Area

HY-P99024

Glofitamab RO7082859	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .

HY-P99711

Loncastuximab RB4v1.2	CD19	Cancer
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .

HY-P99055

Urelumab	TNF Receptor	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-132253

Polatuzumab vedotin	Antibody-Drug Conjugates (ADCs)	Cancer
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-P99851

Detumomab SPECIFID	Inhibitory Antibodies	Cancer
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).

HY-P99501

Zuberitamab HS006	CD20	Cancer
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

HY-P99293

Galiximab IDEC 114; Anti-Human CD80 Recombinant Antibody	CD28	Cancer
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3062

Pinobanksin 3,5,7-Trihydroxyflavanone	Flavanonols Structural Classification Flavonoids Classification of Application Fields Pinaceae Source classification Other Diseases Phenols Polyphenols Plants Pinus morrisonicola Hayata Disease Research Fields	Apoptosis
Pinobanksin has apoptotic induction in a B-cell lymphoma cell line .

HY-N3001

Isolinderalactone	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Lauraceae Lindera aggregata (Sims) Kosterm. Disease Research Fields Cancer	STAT VEGFR Bcl-2 Family Survivin IAP
Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of VEGFR2 activation in endothelial cells . Isolinderalactone suppresses the expression of B-cell lymphoma 2 (Bcl-2), survi

Cat. No.	Product Name	Chemical Structure

HY-A0003S

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

HY-A0003S2

Lenalidomide-13C5,15N

Lenalidomide- ¹³C₅, ¹⁵N is ¹⁵N and ¹³C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .

Cat. No.	Product Name		Classification